Keywords: Sorrento Therapeutics, IGDRASOL, Acquisition option, Breast cancer, NSCLC

Sorrento Therapeutics signs exclusive option to acquire IGDRASOL

Article | 08 March 2013

Print This

USA-based Sorrento Therapeutics, Inc. (SRNE: OB) has signed an exclusive option to acquire IGDRASOL, a private company focused on the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in